v3.26.3
Credit Facility
 12 Months Ended
Jul. 31, 2026
Line of Credit Facility [Abstract]  
Credit Facility Credit Facility
On June 17, 2024, we entered into a senior secured loan facility with a syndicate of lenders, which replaced our prior credit facility. As further discussed below, we subsequently amended the credit facility on October 17, 2024, March 3, 2025, July 21, 2025, June 14, 2026, and July 30, 2026 (the "Credit Facility"). At July 31, 2026, the Credit Facility consists of a remaining $108,519,000 term loan (the "Term Loan" facility) and (ii) an asset-based revolving credit facility with revolving commitments in an aggregate principal amount of $54,750,000, subject to borrowing base limitations as described below (the "Revolving Loan" facility). The obligations under the Credit Facility are guaranteed by certain of our domestic and foreign subsidiaries (the "Guarantors"), who have granted for the benefit of the lenders, a lien on, and first priority security interest in, substantially all of our tangible and intangible assets.
The Credit Facility was amended on October 17, 2024 (the "First Amendment") which, among other things: (i) waived all defaults under the Credit Facility, specifically in connection with our Net Leverage Ratio and Fixed Charge Coverage Ratio covenants as of July 31, 2024; (ii) increased the interest rate margins applicable to the Term Loan to 12.00% per annum for Base Rate Loans and 13.00% per annum for SOFR Loans and increased interest rate margins applicable to the Revolving Loan by 1.00% at each level; (iii) permitted the incurrence of $25,000,000 of total unsecured subordinated debt (as described below); (iv) suspended testing of the Net Leverage Ratio and the Fixed Charge Coverage Ratio covenants until January 31, 2025; (v) provided the lenders a consent right with respect to Revolving Loan borrowings above $32,500,000; and (vi) amended the maturity date to the earlier of: (x) July 31, 2028; or (y) 90 days prior to the earliest date that the debt under the Subordinated Credit Facility (as defined below) becomes due and payable.

The Credit Facility was amended again on March 3, 2025 (the "Second Amendment") which, among other things: (i) waived all defaults under the Credit Facility, specifically in connection with our Net Leverage Ratio and Fixed Charge Coverage Ratio covenants as of January 31, 2025; (ii) decreased the interest rate margins applicable to the Term Loan from 12.00% per annum to 9.50% per annum for Base Rate Loans and from 13.00% per annum to 10.50% per annum for SOFR Loans; (iii) permitted the incurrence of an additional $40,000,000 of total unsecured subordinated debt (as described below); (iv) suspended testing of the Net Leverage Ratio and the Fixed Charge Coverage Ratio covenants until October 31, 2025; (v) suspended our ability to pay interest in-kind until after the interest rate margins are tested based on net leverage ratios; (vi) permitted partial principal repayments of $27,252,000 and $9,084,000 on the Term Loan and Revolving Loan, respectively, and waived the prepayment fees that would have been payable under the Credit Facility with regard to such repayments; (vii) permanently reduced commitments under the Revolving Loan facility by $3,179,000 and provided the lenders a consent right with respect to Revolving Loan borrowings above $29,321,000; (viii) reduced the minimum quarterly average liquidity requirement from $20,000,000 to $17,500,000; and (ix) provided the lenders the right to appoint an independent director to our Board of Directors after May 31, 2025 (which has been satisfied as of the issuance date).

The Credit Facility was further amended on July 21, 2025 (the "Third Amendment") which, among other things: (i) suspended, until the four-quarter period ending January 31, 2027, testing of the Net Leverage Ratio, the Fixed Charge Coverage Ratio and the Minimum EBITDA covenants; (ii) altered the interest rate margins applicable to Term Loans (as described in further detail below); (iii) delayed the scheduled repayment of a portion of the principal of the Term Loans (as described in further detail below); (iv) delayed the scheduled repayment of fees due pursuant to the Second Amendment; (v) reduced the minimum EBITDA requirement (as described in further detail below); (vi) reduced the minimum quarterly average liquidity requirement from $17,500,000 to $15,000,000; (vii) permitted us to engage in the sale or disposition of certain properties and assets approved by the Administrative Agent (the “Specified Permitted Individual Disposition”), on the terms, and subject to documentation, reasonably acceptable to the Administrative Agent, so long as 65% of the net cash proceeds are applied against the outstanding principal amount of the obligations under the Credit Facility and 35% of the net cash proceeds are applied against the outstanding principal amount of the subordinated term loans under the Subordinated Credit Facility (as defined below); and (viii) required us to adopt management incentive and retention arrangements for our key personnel in connection with the contemplation of our strategic alternatives.

The Third Amendment provided that the interest rate margins on the Term Loans would be 9.50% and 10.50% for Base Rate Loans and SOFR Loans, respectively, until the first business day of the month following January 31, 2027, when we were to have delivered financial statements demonstrating compliance with the financial covenants under the Credit Facility. If demonstrated, the interest rate margins would have reverted to: (i) for Base Rate Loans, a margin ranging from 7.50% to 9.00% and (ii) for SOFR Loans, a margin ranging from 8.50% to 10.00%, in each case, based on whether our Net Leverage Ratio during the applicable determination period ranges from less than 1.75x to greater than or equal to 3.25x, respectively.
The Third Amendment deferred $3,037,500 of scheduled term loan repayments otherwise due on July 31, 2025 until: (x) the maturity of the Credit Facility, or (y) January 31, 2026, in the case that we had not filed by December 31, 2025, either (i) a Form 10-K annual report accompanied by an opinion of our independent registered public accounting firm free from any “going concern” or like qualification or exception with respect to our consolidated financial statements for the relevant fiscal year ended, or (ii) a Form 10-Q quarterly report that included footnote disclosure (with which our independent registered public accounting firm would not disagree) in the financial statements accompanied thereby that affirmatively included management's assessment that there is no longer a substantial doubt about our ability to continue as a going concern. With the filing of our prior year Form 10-K for the fiscal year ended July 31, 2025, the $3,037,500 became due upon the maturity of the Credit Facility.

On June 14, 2026, in connection with entering into the Strategic Transaction, we amended the Credit Facility (the "Fourth Amendment") which, among other things: (a) provides consent to the consummation of the Strategic Transaction; (b) acknowledges and agrees that the Strategic Transaction shall not result in a Change of Control as defined in the Credit Facility, as amended; (c) suspends, through the four quarter period ending July 31, 2027, testing of the Net Leverage Ratio, Fixed Charge Coverage Ratio and Minimum EBITDA covenants; (d) clarifies that the Advance Payment will not be required to be applied to prepay the applicable obligations in accordance with the terms of the Credit Facility until the Strategic Transaction closes; and (e) provides that the Maximum Revolver Amount under the Credit Facility shall not be reduced to an amount less than $27,250,000 as a result of the prepayment of the Term Loan in accordance with the terms of Credit Facility. The Fourth Amendment also: (i) sets the applicable margin for Base Rate Loans and SOFR Loans at 9.50% and 10.50%, respectively, through the maturity of the Credit Facility; (ii) provides for a fee to be applied to the Term Loan balance outstanding at various intervals after the closing of the sale of most of S&S' business; and (iii) reduces the prepayment penalty associated with the application of the net proceeds from the sale of most of S&S' business by 1.00%. On July 30, 2026, we further amended the Credit Facility (the "Fifth Amendment") to, among other things, waive any excess cash flow prepayment that would have been payable for the fiscal year ended July 31, 2026.

Once financial covenant testing resumes on July 31, 2027, in addition to complying with the minimum quarterly average liquidity requirement, we will be required to comply with: (i) a maximum Net Leverage Ratio of 2.65x commencing with the four fiscal quarter period ending July 31, 2027 and thereafter; (ii) a minimum Fixed Charge Coverage Ratio of 1.35x commencing with the four fiscal quarter period ending July 31, 2027 and thereafter; and (iii) a minimum EBITDA of $37,500,000 for the four-quarter period ending July 31, 2027 and $40,000,000 for the four-quarter period ending October 31, 2027 and thereafter.

We accounted for the October 17, 2024, March 3, 2025, July 21, 2025, June 14, 2026 and July 30, 2026 amendments to our Credit Facility as debt modifications.

At the time of entering into the Third Amendment in fiscal 2025, and through and including the issuance date, there were no events of default. Over the next twelve months beyond the issuance date, we believe that it is probable we will be able to comply with the covenants required by the Credit Facility.

In accordance with our existing credit facilities, we must use 65% of the net proceeds from the Strategic Transaction to prepay the majority of our Credit Facility, with the remaining 35% used to prepay debt outstanding under our Subordinated Credit Facility, starting with repaying the subordinated priority term loan. As a result of these contractual repayment obligations, and given that the Disposal Group met the criteria to be reported as "held for sale" as of year end, $85,347,000 of the Term Loan outstanding under the Credit Facility (including principal, and excluding deferred financing costs and debt discounts) was classified as current liabilities in our Consolidated Balance Sheet as of July 31, 2026.
Additional Credit Facility Details

In connection with entering the Credit Facility, the Term Loan lenders received 1,435,884 detachable warrants (as amended, the "Lender warrants") granted at an exercise price of $0.10 per common share which entitles the Term Loan lenders to purchase 1,435,884 shares of our common stock from us at any time and from time to time after the Closing Date and on or prior to June 17, 2031, subject to certain adjustments. Upon the earlier of the consummation of the Strategic Transaction or refinancing of the Term Loan, the Term Loan lenders have the right to sell up to 50.0% of the warrants back to us for cash, at a 10.0% discount to the 30-day volume weighted average price of our common stock, subject to certain adjustments. We determined that the Lender warrants met the definition of a freestanding financial instrument that should be accounted for as a liability. We established an initial Lender warrant liability of $3,011,000 which was allocated as a discount against the Term Loan proceeds. The Lender warrant liability is classified in "Warrant and derivative liabilities" on the Consolidated Balance Sheets and is remeasured to its estimated fair value each reporting period, using Level 3 fair value inputs, until the Lender warrants are exercised or expire. Changes in the estimated fair value of the Lender warrant liability are recognized in our Consolidated Statement of Operations as a non-cash expense or benefit. As of July 31, 2026 and 2025, the Lender warrant liability was remeasured to $2,303,000 and $3,007,000, respectively, resulting in a non-cash benefit of $704,000 and $1,537,000 for the years ended July 31, 2026 and 2025, respectively, recorded in "Other expenses (income) - Change in fair value of warrants and derivatives" on the Consolidated Statements of Operations.

Additionally, we identified several embedded derivatives that require bifurcation from the Credit Facility under ASC 815-15 - "Embedded Derivatives," ("ASC 815"). Certain of these embedded features include contingent event of default, going concern interest rate increases and/or fees, which qualify for accounting as one combined embedded derivative liability. We established an initial embedded derivative liability of $3,116,000, which was allocated as a discount against the Term Loan proceeds. The combined embedded derivative liability is presented with the host instrument as part of the amount outstanding under the Credit Facility on the Consolidated Balance Sheets and is remeasured to its estimated fair value each reporting period, using Level 3 fair value inputs, until the embedded derivative features have zero probability of occurring or expire. Changes in the estimated fair value of the combined embedded derivative liability are recognized in our Consolidated Statement of Operations as a non-cash expense or benefit. As of July 31, 2026 and 2025, the combined embedded derivative liability was remeasured to $601,000 and $1,890,000, respectively, resulting in non-cash benefits of $1,289,000 and $1,151,000 for the years ended July 31, 2026 and 2025, respectively, recorded in "Other expenses (income) - Change in fair value of warrants and derivatives" on the Consolidated Statements of Operations.

The following table summarizes the activity relating to deferred financing costs and discounts under the Credit Facility:

Deferred Financing CostsDiscount
Term LoanRevolverTotalTerm LoanTotal
Credit facility fees$6,626,000 3,353,000 $9,979,000 $7,486,000 $17,465,000 
Term loan proceeds allocated to lender
  warrants		— — — 3,011,000 3,011,000 
Term loan proceeds allocated to
  embedded derivative		— — — 3,116,000 3,116,000 
Amendment fees— 975,000 975,000 9,326,000 10,301,000 
Write-off due to prepayments and
  reduced commitments		(1,788,000)(1,707,000)(3,495,000)(5,482,000)(8,977,000)
Amortization(1,315,000)(714,000)(2,029,000)(3,653,000)(5,682,000)
Balance at July 31, 2025
$3,523,000 1,907,000 $5,430,000 $13,804,000 $19,234,000 
Amendment fees— 190,000 190,000 580,000 770,000 
Write-off due to voluntary
      prepayment		(128,000)— (128,000)(530,000)(658,000)
Amortization (1,232,000)(643,000)(1,875,000)(4,906,000)(6,781,000)
Balance at July 31, 2026
$2,163,000 1,454,000 $3,617,000 $8,948,000 $12,565,000 
Deferred financing fees and discounts attributable to the Term Loan are amortized as interest expense over the life of the debt through the maturity date using the effective interest method and are presented as a deduction to the borrowings outstanding under the Term Loan. Deferred financing fees attributable to the Revolving Loan are capitalized on the Consolidated Balance Sheets and amortized as interest expense over the life of the debt using the straight-line method.

The amount outstanding under our Credit Facility was as follows:
July 31, 2026July 31, 2025
Current Portion:
   Term loan$85,347,000 4,050,000 
   Less: Unamortized deferred financing costs related to term loan1,701,000 — 
   Less: Unamortized discount related to term loan7,037,000 — 
   Current portion of term loan, net$76,609,000 4,050,000 
Non-current Portion:
   Term loan $23,172,000 112,210,000 
   Less: Unamortized deferred financing costs related to term loan462,000 3,523,000 
   Less: Unamortized discount related to term loan1,911,000 13,804,000 
   Non-current portion of term loan, net20,799,000 94,883,000 
   Revolving loan— 17,641,000 
   Embedded derivative related to Credit Facility601,000 1,890,000 
   Non-current portion of Credit Facility, net$21,400,000 114,414,000 

During the fiscal year ended July 31, 2026, we had outstanding balances under our Credit Facility ranging from $108,519,000 to $135,305,000.

Availability under the Revolving Loan is subject to eligibility criteria set forth in the Credit Facility, and equal to a borrowing base in an amount equal to, from time to time: (a) 85% of the consolidated net book value of billed and invoiced accounts receivable; plus (b) 85% of the consolidated net book value of accounts receivable we have the right to bill but have not yet billed up to the lesser of (i) 12.5% of the amount calculated pursuant to the sum of clauses (a) and (b) and (ii) $15,000,000 of such accounts; plus (c) 60% of the consolidated net book value of all inventory, less (d) customary reserves. As of July 31, 2026 and July 31, 2025, our eligible Borrowing Base collateral, as defined under the Revolving Loan, was $92,727,000 and $101,222,000, respectively.

Interest expense for fiscal 2026 and 2025 related to our Credit Facility, including amortization of deferred financing costs and debt discount and minimum interest and unused line fees related to the Revolving Loan, as applicable, allocated to: (i) continuing operations was $6,809,000 and $14,877,000, respectively, and (ii) discontinued operations was $18,526,000 and $19,836,000, respectively. Our blended interest rate approximated 19.76%, and 18.51% for fiscal 2026 and 2025, respectively.

The Term Loan is subject to 2.50% amortization per annum. Scheduled Term Loan repayments of $1,012,500 are payable on the last business day of each fiscal quarter, with the remaining Term Loan balance due on the maturity date. On July 31, 2026, in addition to the scheduled quarterly Term Loan repayment of $1,012,500, we made a voluntary prepayment of $6,500,000, which was applied to future scheduled quarterly Term Loan repayments. As such, the next scheduled quarterly Term Loan repayment of $587,500 is due on April 30, 2028.
The Credit Facility contains: (a) customary representations, warranties and affirmative covenants; (b) customary conditions to drawing the Revolving Loan; (c) customary negative covenants, subject to negotiated exceptions, including but not limited to: (i) liens, (ii) investments, (iii) indebtedness, (iv) significant corporate changes, including mergers and acquisitions, (v) dispositions, including the disposition of assets by any Loan Party to any Subsidiary that is not a Loan Party, (vi) restricted payments, including stockholder dividends, (vii) distributions, including the repayment of subordinated intercompany and third party indebtedness, and (viii) certain other restrictive agreements; (d) certain financial covenants (see above); (e) customary optional and mandatory prepayment events; and (f) customary events of default (subject to grace periods, as appropriate), such as payment defaults, cross-defaults to other material indebtedness, bankruptcy and insolvency, the occurrence of a defined change in control and the failure to observe the negative covenants and other covenants related to the operation of our business. In addition, under certain circumstances, we may be required to enter into amendments to the Credit Facility in connection with any further syndication of the Credit Facility.

Capitalized terms used but not defined herein have the meanings set forth for such terms in the Credit Facility, which has been documented and filed with the SEC.
Subordinated Credit Facility
On October 17, 2024, we entered into a subordinated credit facility with the existing holders of our convertible preferred stock and U.S. Bank Trust Company, National Association, as agent, which provided an initial subordinated unsecured term loan facility in the aggregate principal amount of $25,000,000 (the “Subordinated Credit Agreement”). As further discussed below, on March 3, 2025, July 21, 2025, June 14, 2026 and July 30, 2026, we entered into amendments to the Subordinated Credit Agreement (the "Subordinated Credit Facility”).

On March 3, 2025, we entered into an amendment ("Amendment No. 1") which, in addition to providing incremental aggregate principal of $40,000,000, waived all defaults under the Subordinated Credit Facility, specifically in connection with our Net Leverage Ratio and Fixed Charge Coverage Ratio covenants as of January 31, 2025 and suspended testing of the Net Leverage Ratio and the Fixed Charge Coverage Ratio covenants under the Subordinated Credit Facility until October 31, 2025. The net proceeds were principally used to repay a portion of the Term Loan and Revolving Loan on March 3, 2025, fund our general working capital needs and enabled us to negotiate the Second Amendment to the Credit Facility, including the waiver of existing defaults.

On July 21, 2025, we entered into a second amendment (“Amendment No. 2”) which, among other things: (i) provided for the incurrence of a $35,000,000 incremental facility (as described in further detail below); (ii) suspended, until the four-quarter period ending January 31, 2027, testing of the Net Leverage Ratio, the Fixed Charge Coverage Ratio and the Minimum EBITDA covenants in the Subordinated Credit Facility; (iii) modified the interest rate applicable to the subordinated term loans (as described in further detail below); (iv) reduced the minimum EBITDA requirement (as described in further detail below); (v) reduced the minimum quarterly average liquidity requirement from $17,500,000 to $15,000,000; (vi) permitted us to engage in the Specified Permitted Individual Disposition, on the terms, and subject to documentation, reasonably acceptable to the Subordinated Agent (subject to the same requirement with respect to the application of any net cash proceeds as discussed in Note (8) - Credit Facility); and (vii) required us to adopt management incentive and retention arrangements for its key personnel in connection with the contemplation of our strategic alternatives (also as discussed Note (8) - Credit Facility).

Amendment No. 2 provides for an incremental priority subordinated unsecured term loan facility in the aggregate principal amount of $35,000,000. We used the net proceeds to pay certain transaction costs, fees and expenses incurred in connection with amendments to our credit facilities and to prepay, without premium: (i) $28,481,000 of the outstanding Term Loans under the Credit Facility, and (ii) $5,775,000 of the outstanding Revolving Loan under the Credit Facility. As part of this prepayment, we permanently reduced Revolving Loan commitments under the Credit Facility by $2,071,000. The interest on the priority subordinated credit facility term loan shall be paid-in-kind quarterly, in arrears, by capitalizing and adding the unpaid and accrued amount of such interest to the aggregate outstanding principal amount of the priority subordinated credit facility term loan on the last business day of each quarter. This tranche of subordinated debt ranks senior in right of payment to the existing subordinated term loans under the Subordinated Credit Facility. Unlike the existing subordinated term loans, the incremental priority subordinated credit facility is not subject to any make-whole premium.
Under Amendment No. 2, the interest rate applicable to the incremental priority subordinated credit facility shall be the greater of: (x) the highest per annum interest rate then-applicable to the Term Loans under the Credit Facility, and (y) Term SOFR (as defined in the Credit Facility) plus 10.5%.

On June 14, 2026, we entered into a third amendment (“Amendment No. 3”) which, among other things: (a) provides consent to the consummation of the Strategic Transaction; (b) acknowledges and agrees that the Strategic Transaction shall not result in a Change of Control as defined in the Subordinated Credit Facility; (c) suspends, through the four quarter period ending July 31, 2027, testing of the Net Leverage Ratio, Fixed Charge Coverage Ratio and Minimum EBITDA covenants; (d) clarifies that the Advance Payment will not be required to be applied to prepay the applicable obligations in accordance with the terms of the Subordinated Credit Facility until the Strategic Transaction closes; and (e) modifies the calculation of the Make-Whole Amount applicable to certain tranches of subordinated term loans by deferring the respective trigger dates for such Make-Whole Amount adjustments to April 1, 2027. In connection with Amendment No. 3, we also issued warrants to certain subordinated lenders to purchase up to 625,000 shares of our common stock at an exercise price of $0.10 per share. The warrants, and the shares of our common stock underlying the warrants, will vest and become exercisable on October 17, 2026, and are automatically and irrevocably forfeitable if the related subordinated term loans (including, without limitation, payment of (x) all accrued and unpaid interest thereon and (y) the applicable Make-Whole Amount payable in connection therewith) are repaid in full prior to vesting.

Under Amendment No. 3, once financial covenant testing resumes on July 31, 2027, in addition to complying with the minimum quarterly average liquidity requirement, we will be required to comply with: (i) a maximum Net Leverage Ratio of 3.18x as of July 31, 2027 and thereafter; (ii) a minimum Fixed Charge Coverage Ratio of 1.08x commencing with the four fiscal quarter period ending July 31, 2027 and thereafter; and (iii) a minimum EBITDA of $30,000,000 for the four-quarter period ending July 31, 2027 and $32,000,000 for the four-quarter period ending October 31, 2027 and thereafter.

On July 30, 2026, we entered into a fourth amendment (“Amendment No. 4”) to, among other things make certain technical amendments with respect to the application of a prepayment of outstanding amounts under the Subordinated Credit Facility.

At the time of entering into Amendment No. 2 in fiscal 2025, and through and including the issuance date, there were no events of default. Over the next twelve months beyond the issuance date, we believe that it is probable we will be able to comply with the covenants required by the Subordinated Credit Facility.

On July 31, 2026, we made a $3,500,000 voluntary prepayment under the Subordinated Credit Facility, which was applied to the priority subordinated credit facility term loan, including interest paid-in-kind.

In accordance with our existing credit facilities, we must use 65% of the net proceeds from the sale of most of our S&S business to prepay the majority of our Credit Facility, with the remaining 35% used to prepay debt outstanding under our Subordinated Credit Facility, starting with repaying the remaining portion of the subordinated priority term loan. As a result of these contractual repayment obligations, and given that the Disposal Group met the criteria to be reported as "held for sale" as of year end, $45,956,000 of the term loans outstanding under the Subordinated Credit Facility including principal, interest paid-in-kind and Make Whole Amounts, as applicable, and excluding deferred financing costs and debt discounts) were classified as current liabilities in our Consolidated Balance Sheet as of July 31, 2026.

Debt related to the Subordinated Credit Facility will not be considered debt for purposes of our financial covenant testing under the Credit Facility. However, the Subordinated Credit Facility includes a cross-default provision, whereby a default under the Credit Facility constitutes a default under the Subordinated Credit Facility.
Additional Subordinated Credit Facility Details

The obligations under the Subordinated Credit Facility mature 90 days after the Credit Facility. Unlike the $35,000,000 tranche discussed above, the other two tranches of the Subordinated Credit Facility, which aggregate $65,000,000 of principal, are subject to Make-Whole Amounts with respect to certain repayments or prepayments equal to: (i) from the respective closing date of each tranche through (but not including) the date that is nine months thereafter, the principal repayment amount multiplied by 33.0%; (ii) from the date that is nine months after the applicable closing date through (but not including) April 1, 2027, the principal repayment amount multiplied by 50.0% plus, starting on March 3, 2027, interest accrued on the principal amount outstanding at the Make-Whole Interest Rate (as defined below) and calculated as of any such date of determination; (iii) from April 1, 2027 and thereafter, the principal repayment amount multiplied by 75.0% plus, starting on April 1, 2027, interest accrued on the principal amount outstanding at the Make-Whole Interest Rate (as defined below) and calculated as of any such date of determination. The Make-Whole Interest Rate is a rate equal to 16.0% per annum, which is increased by 2.0% per annum upon the occurrence and during the continuation of an event of default under the Subordinated Credit Facility.

We identified an embedded derivative related to redemption features that requires bifurcation from the Subordinated Credit Facility under ASC 815. We established a total embedded derivative liability of $16,864,000, which was allocated as a discount against the Subordinated Credit Facility proceeds. The embedded derivative liability is presented with the "Non-current portion of subordinated credit facility, net" on the Consolidated Balance Sheet and is remeasured to its estimated fair value each reporting period, using Level 3 fair value inputs, until the embedded derivative redemption features have zero probability of occurring or expire. Changes in the estimated fair value of the embedded derivative liability are recognized in our Consolidated Statements of Operations as a non-cash expense or benefit. For the fiscal years ended July 31, 2026 and 2025, the embedded derivative liability was remeasured to zero and $5,753,000, respectively. For the fiscal years ended July 31, 2026 and 2025, we recorded a non-cash benefit of $5,753,000 and $11,111,000 in "Other expenses (income) - Change in fair value of warrants and derivatives" on the Consolidated Statements of Operations.

In connection with Amendment No. 3, we issued warrants to the subordinated lenders to purchase up to 625,000 shares of our common stock at an exercise price of $0.10 per share. The warrants vest on October 17, 2026, expire on April 17, 2032 and are forfeitable if the related subordinated term loans are repaid in full prior to vesting. We determined that the warrants met the definition of a freestanding financial instrument that should be accounted for as a liability. We established an initial warrant liability of $1,678,000, which was allocated as a discount against the Subordinated Credit Facility term loans. The warrant liability is classified in "Warrant and derivative liabilities" on the Consolidated Balance Sheets and is remeasured to its estimated fair value each reporting period, using Level 3 fair value inputs, until the warrants are forfeited, exercised or expire. Changes in the estimated fair value of the warrant liability are recognized in our Consolidated Statement of Operations as a non-cash expense or benefit. As of July 31, 2026, the warrant liability was remeasured to $1,005,000, resulting in a non-cash benefit of $673,000 for the year ended July 31, 2026, recorded in "Other expenses (income) - Change in fair value of warrants and derivatives" on the Consolidated Statements of Operations.

Deferred financing costs, discounts and the Make-Whole Amount are amortized as interest expense through the Subordinated Credit Facility maturity date using the effective interest method, and are presented as adjustments to the borrowings outstanding under such debt.

Interest expense for fiscal 2026 and 2025 related to our Subordinated Credit Facility, including amortization of deferred financing costs, debt discount and the Make-Whole Amount, allocated to: (i) continuing operations was $14,507,000 and $4,084,000; and (ii) discontinued operations was $8,410,000 and $6,793,000 respectively. We accounted for all of the amendments to date as debt modifications.
The following table reconciles the amount outstanding under the Subordinated Credit Facility to its net carrying value:
July 31, 2026July 31, 2025
Current Portion:
  Subordinated Credit Facility$42,987,000 — 
  Less: Unamortized deferred financing costs124,000 — 
  Less: Unamortized discount1,424,000 — 
  Plus: Accretion of Make-Whole Amount2,969,000 — 
  Current portion of Subordinated Credit Facility, net$44,408,000 — 
Non-current Portion:
   Subordinated Credit Facility$59,062,000 100,144,000 
   Less: Unamortized deferred financing costs1,065,000 1,528,000 
   Less: Unamortized discount12,174,000 15,404,000 
   Plus: Accretion of Make-Whole Amount17,097,000 6,623,000 
   Non-current portion of Subordinated Credit Facility, net -subtotal62,920,000 89,835,000 
   Embedded derivative related to redemption features— 5,753,000 
   Non-current portion of Subordinated Credit Facility, net$62,920,000 95,588,000 

The obligations under the Subordinated Credit Facility are guaranteed by the same guarantors under the Credit Facility and contain customary representations, warranties and affirmative covenants, in each case substantially consistent with the representations and warranties and affirmative covenants under the Credit Facility. The Subordinated Credit Facility contains customary negative covenants, subject to negotiated exceptions, including but not limited to: (i) liens, (ii) investments, (iii) indebtedness, (iv) significant corporate changes, including mergers and acquisitions, (v) dispositions, (vi) restricted payments, including stockholder dividends, (vii) customary optional and mandatory prepayment events, and (viii) certain other restrictive agreements.

Capitalized terms used but not defined herein have the meanings set forth for such terms in the Subordinated Credit Facility, which has been documented and filed with the SEC.